Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof

The disclosure relates to a novel dosage form comprising hard gelatin capsule having granule composition, spray dried or evaporated composition containing tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine and tablet comprising tafamidis or its pharmaceutically accept...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Balaiah, Erugu, Shanmugam, Muthusamy, Venkatragavan, Ramasamy, Sakthikumar, Thirunavukkarasu, Madhukar, Singavarapu Ajay, Sivakumar, Palanisamy
Format:	Patent
Sprache:	eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	Balaiah, Erugu Shanmugam, Muthusamy Venkatragavan, Ramasamy Sakthikumar, Thirunavukkarasu Madhukar, Singavarapu Ajay Sivakumar, Palanisamy
description	The disclosure relates to a novel dosage form comprising hard gelatin capsule having granule composition, spray dried or evaporated composition containing tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine and tablet comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine that would not form a rigid gel upon contacting with water or buffer solution in dissolution specifically pH 6.8 phosphate buffer and that composition is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US11523993B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US11523993B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US11523993B13</originalsourceid><addsrcrecordid>eNqNzDsOwjAQRdE0FAjYw7AACmNRpOUnRAvU0cMZJ5bs2PIMBbuHggVQ3ebozpvrMQsGJp9rEsqeFB4p9EEIU09BhcqImuD4pcEhxjfBOS6KZ2QSRCUduXL2y2bmEYVXvy6a9fl0P1w2XHLHUr6LibV73IzZbW3b2r2x_5gPJKU1Vg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof</title><source>esp@cenet</source><creator>Balaiah, Erugu ; Shanmugam, Muthusamy ; Venkatragavan, Ramasamy ; Sakthikumar, Thirunavukkarasu ; Madhukar, Singavarapu Ajay ; Sivakumar, Palanisamy</creator><creatorcontrib>Balaiah, Erugu ; Shanmugam, Muthusamy ; Venkatragavan, Ramasamy ; Sakthikumar, Thirunavukkarasu ; Madhukar, Singavarapu Ajay ; Sivakumar, Palanisamy</creatorcontrib><description>The disclosure relates to a novel dosage form comprising hard gelatin capsule having granule composition, spray dried or evaporated composition containing tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine and tablet comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine that would not form a rigid gel upon contacting with water or buffer solution in dissolution specifically pH 6.8 phosphate buffer and that composition is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221213&DB=EPODOC&CC=US&NR=11523993B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221213&DB=EPODOC&CC=US&NR=11523993B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Balaiah, Erugu</creatorcontrib><creatorcontrib>Shanmugam, Muthusamy</creatorcontrib><creatorcontrib>Venkatragavan, Ramasamy</creatorcontrib><creatorcontrib>Sakthikumar, Thirunavukkarasu</creatorcontrib><creatorcontrib>Madhukar, Singavarapu Ajay</creatorcontrib><creatorcontrib>Sivakumar, Palanisamy</creatorcontrib><title>Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof</title><description>The disclosure relates to a novel dosage form comprising hard gelatin capsule having granule composition, spray dried or evaporated composition containing tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine and tablet comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine that would not form a rigid gel upon contacting with water or buffer solution in dissolution specifically pH 6.8 phosphate buffer and that composition is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNzDsOwjAQRdE0FAjYw7AACmNRpOUnRAvU0cMZJ5bs2PIMBbuHggVQ3ebozpvrMQsGJp9rEsqeFB4p9EEIU09BhcqImuD4pcEhxjfBOS6KZ2QSRCUduXL2y2bmEYVXvy6a9fl0P1w2XHLHUr6LibV73IzZbW3b2r2x_5gPJKU1Vg</recordid><startdate>20221213</startdate><enddate>20221213</enddate><creator>Balaiah, Erugu</creator><creator>Shanmugam, Muthusamy</creator><creator>Venkatragavan, Ramasamy</creator><creator>Sakthikumar, Thirunavukkarasu</creator><creator>Madhukar, Singavarapu Ajay</creator><creator>Sivakumar, Palanisamy</creator><scope>EVB</scope></search><sort><creationdate>20221213</creationdate><title>Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof</title><author>Balaiah, Erugu ; Shanmugam, Muthusamy ; Venkatragavan, Ramasamy ; Sakthikumar, Thirunavukkarasu ; Madhukar, Singavarapu Ajay ; Sivakumar, Palanisamy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US11523993B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2022</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>Balaiah, Erugu</creatorcontrib><creatorcontrib>Shanmugam, Muthusamy</creatorcontrib><creatorcontrib>Venkatragavan, Ramasamy</creatorcontrib><creatorcontrib>Sakthikumar, Thirunavukkarasu</creatorcontrib><creatorcontrib>Madhukar, Singavarapu Ajay</creatorcontrib><creatorcontrib>Sivakumar, Palanisamy</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Balaiah, Erugu</au><au>Shanmugam, Muthusamy</au><au>Venkatragavan, Ramasamy</au><au>Sakthikumar, Thirunavukkarasu</au><au>Madhukar, Singavarapu Ajay</au><au>Sivakumar, Palanisamy</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof</title><date>2022-12-13</date><risdate>2022</risdate><abstract>The disclosure relates to a novel dosage form comprising hard gelatin capsule having granule composition, spray dried or evaporated composition containing tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine and tablet comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine that would not form a rigid gel upon contacting with water or buffer solution in dissolution specifically pH 6.8 phosphate buffer and that composition is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_US11523993B1
source	esp@cenet
subjects	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title	Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T13%3A30%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Balaiah,%20Erugu&rft.date=2022-12-13&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS11523993B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true